Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol

Aashna Karbhari, Sherly Mosessian, Kamaxi H. Trivedi, Frank Valla Jr, Mark Jacobson, Mark J. Truty, Nandakumar G. Patnam, Diane M. Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H. Kuo, Ken Herrmann, Ajit H. Goenka Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal [...]

November 27th, 2023|Publications|

68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao and Youzhi Zhu Abstract 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer [...]

November 10th, 2023|Publications|

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar Milosevic, Michael Nader, Lale Umutlu, Waldemar Uhl, Anke Reinacher-Schick, Celine Lugnier, David Witte, Marco Niedergethmann, Ken Herrmann, Wolfgang P. Fendler and Jens T. Siveke Abstract The fibroblast activation protein [...]

November 6th, 2023|Publications|

Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT

Weizhi Xu, Jiayu Cai, Tianxing Peng, Tinghua Meng, Yizhen Pang, Long Sun, Hua Wu, Jingjing Zhang, Xiaoyuan Chen and Haojun Chen Abstract Fibroblast activation protein is overexpressed in the stroma of several cancer types. 18F-fibroblast activation protein inhibitor (FAPI)–74 is a PET tracer with [...]

October 20th, 2023|Publications|

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study

Emil Novruzov1, Frederik L Giesel1,2, Yuriko Mori1, Peter L Choyke3, Mardjan Dabir1, Eduards Mamlins1, Dominik Schmitt1, Christina Antke1, Claudio Pinto4, Cristian Soza-Ried5,6, Rene Fernandez5, Horacio Amaral5,6, Vasko Kramer5,6, Leonardo Badinez7 Abstract Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT [...]

August 29th, 2023|Publications|

Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib

Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang Li3, Haitao Zhao2, Li Huo4 Abstract Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG [...]

August 29th, 2023|Publications|

Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco Bertagna5, Salvatore Annunziata6, Giorgio Treglia7,8,9 Abstract Various papers have introduced the use of positron emission tomography (PET) with [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric [...]

August 29th, 2023|Publications|

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Yuriko Mori 1, Katharina Dendl 1, Jens Cardinale 1, Clemens Kratochwil 1, Frederik L Giesel # 1, Uwe Haberkorn # 1 Abstract Gallium 68 (68Ga)-labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of the FAP, which is known to be highly expressed in the major cell population in tumor stroma, termed [...]

February 5th, 2023|Publications|

Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls

Tristan T Demmert 1, Ines Maric 1, Kelsey L Pomykala 2, Katharina Lueckerath 1, Jens Siveke 3, Benedikt M Schaarschmidt 4, Rainer Hamacher 3, Ken Herrmann 1, Wolfgang P Fendler 1 Abstract In the setting of ongoing SARS-CoV-2 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by 18F-FDG PET/CT. 68Ga-FAPI PET/CT is a new oncologic [...]

February 5th, 2023|Publications|

Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer

Philipp Backhaus 1, Matthias C Burg 2, Inga Asmus 1, Michaela Pixberg 1, Florian Büther 1, Hans-Jörg Breyholz 1, Randy Yeh 3, Stefanie B Weigel 2, Patricia Stichling 2, Walter Heindel 2, Stefanie Bobe 4, Peter Barth 5, Joke Tio 6, Michael Schäfers 1 Abstract Rationale: Improving imaging-based response following neoadjuvant chemotherapy (NAC) in breast cancer assessment could obviate the need for histologic confirmation of pathological complete response (pCR) and facilitate de-escalation [...]

November 17th, 2022|Publications|


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top